Pharmaceutical

Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study

NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing…

1 month ago

Curiteva Proudly Announces the Publication of a Peer-Reviewed Study in the Journal of Biomaterials (JBI)

HUNTSVILLE, ALABAMA / ACCESS Newswire / November 13, 2025 / Curiteva, Inc. a privately held manufacturing and technology company, proudly…

1 month ago

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

1 month ago

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™…

1 month ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response…

1 month ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819,…

1 month ago

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

- Combined transactions will strengthen balance sheet and reduce outstanding debt by more than 90% - - $6 million PIPE financing…

1 month ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…

1 month ago

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders,…

1 month ago